Clinical trial NCT02395744: The COPPER-B Trial
Official title: The Occlusion Perfusion Catheter for Optimal Delivery of Paclitaxel for the Prevention of Endovascular Restenosis - Below the Knee
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cardiovascular Diseases
Peripheral Vascular Disease
Arterial Occlusive Diseases
Peripheral Arterial Disease
Critical Limb Ischemia
Lead sponsor: Horizons International Peripheral Group
Sponsor class: OTHER
Collaborators: name: Advanced Catheter Therapies, Inc.
First posted: 2015-03-24
Enrollment: 11
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of the COPPER - B study is to assess the feasibility, safety, and initial efficacy of paclitaxel administration using the OPC for the prevention of restenosis in infrapopliteal de novo and restenotic lesions and occlusions using a novel catheter, the OPC.


Eligibility criteria: General Inclusion Criteria:

* Willing and able to provide informed consent and comply with all study requirements;
* Candidate for an infrapopliteal percutaneous intervention;
* Must be ≥ 18 years of age;
* Rutherford category 3-6;
* Willing and able to tolerate dual anti-platelet therapy (DAPT) for a minimum of one (1) month;
* Labwork within acceptable limits according to standard of care;
* INR \< 2.0 if on warfarin or not on warfarin;
* Sheath size used for the interventional procedure 6F, 7F, or 8F.

General Exclusion Criteria:

* Life expectancy \< one (1) year;
* Planned amputation prior to procedure;
* Pregnancy or nursing (a pregnancy test is required for all women of childbearing capabilities ≤ 7 days prior to the index procedure);
* Previous intervention of the target vessel with a drug eluting balloon, or drug delivery catheter;
* Acute limb ischemia;
* Known allergy to paclitaxel;
* Known hypersensitivity to other drugs manufactured in Cremophor® EL (polyoxyethylated castor oil; e.g. Drugs containing polyoxyethylated castor oil are drugs such as miconazole, cyclosporine injection, nelfinavir mesylate, saperconazole, tacrolimus, and xenaderm ointment);
* Known allergy to anticoagulants;
* Known TRUE acetylsalicylic acid (ASA) allergy;
* Use of glycoprotein (GP) IIb/IIIa inhibitors during the procedure visit within 30 days prior to the index procedure;
* Target lesion treated with a cryoplasty balloon at the time of the index procedure;
* Current enrollment in another investigational device or drug study;
* After obtaining informed consent, at any point up to introduction of the OPC, the investigator determines the study subject is not appropriate for the study;
* Hemorrhagic stroke within three (3) months;
* Renal failure or chronic kidney disease with GFR ≤30 ml/min or MDRD GFR ≤30 ml/min per 1.73 m2 (or serum creatinine ≥2.5 mg/L within 30 days of index procedure or patient is on dialysis);
* Prior vascular surgery of the index limb.

Angiographic Inclusion Criteria

* Reference vessel diameter (RVD) ≥ 2mm and ≤ 4mm;
* Single or multiple lesions in the infrapopliteal arteries (AT, PT, peroneal);
* If single lesion treatment, the minimum lesion length required is 2cm;
* Lesion location must in the area from the origin of the trifurcation vessel to the ankle (top of the talus bone);
* Minimum of one vessel run-off;
* Pre-intervention percent DS ≥ 70%;
* Target vessel reconstitutes at/above the ankle;
* Infrapopliteal treatment prior to infrapopliteal OPC treatment resulting in ≤ 30% residual stenosis;
* Infrapopliteal interventional treatment length is within the area of 1cm below the level of the knee joint to the malleolus, except in the case where an anomalous take-off of an infrapopliteal artery comes of at mid-knee joint.

Angiographic Exclusion Criteria

* Flow limiting dissection requiring stent placement;
* Post PTA residual stenosis \> 30% as visualized by treating physician;
* Perforation requiring a covered stent;
* Lesion is above the trifurcation;
* In-stent restenosis in target vessel;
* Significant (≥ 50% DS) inflow lesion or occlusion left untreated in the ipsilateral Iliac, SFA, or popliteal artery proximal to the target lesion;
* Lesions in the target vessel not treated with the OPC;
* Visible thrombus in the target artery or proximal to the target artery.

Primary outcomes:
measure: Freedom from clinically driven target lesion revascularization (CD-TLR)
timeFrame: 6 months
measure: Freedom from major adverse events (MAEs)
timeFrame: 6 months
Secondary outcomes:
measure: Device success
timeFrame: Index Procedure
measure: Improvement in Rutherford category
timeFrame: 6 Months
measure: Improvement in ABI
timeFrame: 6 months
measure: Freedom from Target Vessel Revascularization
timeFrame: 6 Months
measure: Improvement in wound healing
timeFrame: 6 months
measure: Device or procedure related serious adverse events (SAEs)
timeFrame: 1 month
measure: Treatment related anticipated adverse events (AEs)
timeFrame: 1, 3, and 6 months
measure: Treatment related serious adverse events (SAEs)
timeFrame: 3 and 6 months
Other outcomes:
Locations:
city: Fairhope
country: United States
facility: Cardiology Associates
state: Alabama
city: Houma
country: United States
facility: Cardiovascular Institute of the South
state: Louisiana
city: Dearborn
country: United States
facility: Michigan Outpatient Vascular Institute
state: Michigan
city: Tyler
country: United States
facility: Cardiovascular Associates of East Texas
state: Texas
Study officials:
affiliation: Cardiology Associates
name: Frank Bunch, MD, FACC
role: PRINCIPAL_INVESTIGATOR
References: